KRON Kronos Bio

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results.

Fourth Quarter and Full Year 2024 Financial Results

  • Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.

  • R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense of $3.4 million.

  • G&A Expenses: General and administrative expenses were $4.9 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $1.0 million. For the full year of 2024, general and administrative expenses were $24.6 million, which includes non-cash stock-based compensation expense of $5.8 million.

  • Impairment of long-lived assets and restructuring: Impairment of long-lived assets and restructuring charges were $16.1 million for the fourth quarter of 2024, which includes non-cash impairment charges of $11.6 million and non-cash stock-based compensation expense of $0.5 million. For the full year of 2024, Impairment of long-lived assets and restructuring charges were $29.5 million, which includes non-cash impairment charges of $18.7 million and non-cash stock-based compensation expense of $4.9 million.

  • Net loss: Net loss for the fourth quarter of 2024 was $25.8 million, or $0.43 per share, including non-cash stock-based compensation expense of $2.2 million. Net loss for the full-year 2024 was $86.1 million, or $1.43 per share, including non-cash stock-based compensation expense of $14.1 million.

About Kronos Bio

Kronos Bio is a biopharmaceutical company that has historically focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases. In November 2024, we announced a process to evaluate potential strategic alternatives focused on maximizing stockholder value, including, but not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, or other strategic transactions. Our activities to evaluate and pursue potential strategic alternatives may not result in any transaction or enhance stockholder value. Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit or follow the Company on LinkedIn.



Kronos Bio, Inc.

Condensed Statements of Operations and Comprehensive Loss

(in thousands, except per share data)

(Unaudited)



 Three Months Ended December 31,Year Ended December 31,
  2024  2023   2024  2023 
Revenue$2,270  $2,286  $9,848  $6,288 
Operating expenses:       
Research and development 8,409   18,704   48,664   84,515 
General and administrative 4,924   9,213   24,616   38,974 
Impairment of long-lived assets and restructuring 16,091   1,960   29,455   4,876 
Total operating expenses 29,424   29,877   102,735   128,365 
Loss from operations (27,154)  (27,591)  (92,887)  (122,077)
Other income (expense), net:       
Interest income and other expense, net 1,341   2,271   6,808   9,404 
Total other income (expense), net 1,341   2,271   6,808   9,404 
Net loss (25,813)  (25,320)  (86,079)  (112,673)
Other comprehensive income (loss):       
Net unrealized gain (loss) on available-for-sale securities (15)  274   (10)  811 
Net comprehensive loss$(25,828) $(25,046) $(86,089) $(111,862)
Net loss per share, basic and diluted$(0.43) $(0.43) $(1.43) $(1.95)
Weighted-average number of shares used to compute net loss per share, basic and diluted 60,344   58,268   60,070   57,744 
 



Kronos Bio, Inc.

Selected Balance Sheet Data

(in thousands)

(Unaudited)



 December 31, 2024 December 31, 2023
Cash, cash equivalents and investments$        112,422 $        174,986
Total assets$        124,363 $        213,279
Total liabilities$        36,783 $        54,201
Total stockholders’ equity$        87,580 $        159,078
      


Contact:
 
EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kronos Bio

 PRESS RELEASE

Kronos Bio Enters into Agreement to Be Acquired by Concentra Bioscienc...

Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC ( “Concentra”), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share...

 PRESS RELEASE

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based co...

 PRESS RELEASE

Kronos Bio Announces CEO Transition and Reduction in Force

Kronos Bio Announces CEO Transition and Reduction in Force – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective D...

 PRESS RELEASE

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors R...

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 – Preclinical data demonstrate the ability of p300 KAT inhibition to modulate multiple pro-inflammatory signaling pathways, including antibodies and cytokine production, in ex vivo and in vivo models at well tolerated exposures – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcrip...

 PRESS RELEASE

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate ...

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives – Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does not support further development – – Kronos Bio Board of Directors has approved plan to evaluate strategic alternatives to maximize stockholder value – – Kronos Bio’s additional pipeline assets include preclinical p300 KAT inhibitor programs in oncology and autoimmune disease – — $124.9 million cash, cash equivalents, and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch